McLaren-Greater Lansing

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Triple-negative breast cancer2 trials
• Atrial fibrillation1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Obesity1 trial
• Peripheral artery disease1 trial
• Prostate cancer1 trial

Phase

• Phase 36 trials
• Phase 23 trials

Status

• Active, not recruiting8 trials
• Completed4 trials

Lead sponsor

• ECOG-ACRIN Cancer Research Group3 trials
• Alliance for Clinical Trials in Oncology2 trials
• SWOG Cancer Research Network2 trials
• Heart Rhythm Clinical and Research Solutions, LLC1 trial
• Novartis Pharmaceuticals1 trial
• and 3 more

Running trials

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

  NCT04562532· Shanghai MicroPort Medical (Group) Co., Ltd.· Source

• Active, not recruiting

  Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

  NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

  NCT04088071· Heart Rhythm Clinical and Research Solutions, LLC· Source

  Contact: April Bond, MS

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Closed trials

• Completed

  Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

  NCT05007925· Shockwave Medical, Inc.· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

  NCT03633331· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source